Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Zevor-Cel Shows Long-Term Efficacy in Small R/R Multiple Myeloma Population
2
Multiantigen-Targeted T Cells Safe/Feasible in Locally Advanced PDAC
3
mRNA Vaccine/Pembrolizumab Shows Sustained 5-Year RFS in High-Risk Melanoma
4
T-DXd/Pertuzumab Earns Type II Application Validation in EU for HER2+ mBC
5